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Abstract 
Scientists throughout the world are searching for a lasting solution in the form of a vaccine or 
a drug that could be used to combat COVID-19 infections. A number of studies have 
proposed the antiviral efficacy of mouthwashes across a different population. Research has 
shown over the years that active ingredients present in commercially available mouthwash 
are potent enough to damage viruses, particularly those with the lipid envelope, rendering 
them harmless. This paper reviews the effect of mouthwashes on few viruses, including those 
possibly linked to SARS-COV-2. The aim is to provide evidence on the potential benefit of 
mouthwashes in reducing viral load and pool together the impact of various mouthwashes in 
managing individuals diagnosed with viral infections. We searched academic, English-
scripted paper published between 1995 and June 2020 on PubMed, MEDLINE, 
ScienceDirect, EMBASE, WHO and the Cochrane Library databases. Two review authors 
independently assessed the eligibility and quality of the retrieved papers using the Jadad 
scale. Result showed there were evidences indicating that the benefits of mouthwashes to 
viral infections might be transferrable to COVID-19. However, future trials are recommended 
to establish the benefits of mouthwashes in reducing the burden of COVID-19. 
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BACKGROUND 
Coronaviruses (CoVs) are a group of viruses, which belong to the family of Coronaviridae, 
the largest family in the order of Nidovirales (Pal et al., 2020). Coronaviruses are positive-
stranded RNA which depends on the fusion of their envelope with the host cell membrane 
(Belouzard et al., 2010). Coronaviruses were first isolated in animals; first in chickens in 
1931 known as infectious bronchitis virus (Shalk, 1931) and then mouse hepatitis virus was 
isolated in mouse in 1940 (Cecílio, 2000). In subsequent years, other coronaviruses such as 
transmissible gastroenteritis virus (TGEV) and Porcine epidemic diarrhoea virus (PEDV) 
causing severe gastro and respiratory disease in pigs, cows, dogs, cats and chickens (Liu & 
Gerdts, 2019; Paules et al., 2020) were identified. The animal coronavirus mostly leads to 
enteric infection and the ability to infect the nervous system, causing encephalitis and 
vomiting, leading to significant morbidity and mortality (Paules et al., 2020).
 
 
Human coronaviruses were first discovered in the 1960s after it was isolated in the UK at the 
common cold unit of the British Medical Research Council from a boy with common cold 
symptoms (Kendall et al., 1962). The virus was uncultivable using standard techniques, until 
serially passed through an organ culture of the human embryonic trachea (Tyrell & Bynoe, 
1965). Initially, there were six human coronaviruses with varying levels of severity, which 
are all capable of producing potentially severe symptoms (Pal et al., 2020). The first is 229E, 
a coronavirus species responsible for the common cold; second is NL63, associated with mild 
to moderate upper respiratory tract infections and severe lower respiratory tract infection. The 
third is OC43, which is a coronavirus responsible for the common cold; the fourth is HKU1, 
responsible for the upper respiratory tract. The fifth human coronavirus in the Middle East 
respiratory syndrome-related coronavirus (MERS-CoV), which is the cause of the MERS 
disease. Severe acute respiratory syndrome coronavirus (SARS-CoV) is the sixth human 
coronavirus, first identified in Shunde, China (Pal et al., 2020). 
 
In December 2019, a novel coronavirus genetically, related to SARS-CoV was isolated in 
Wuhan, China, becoming the seventh human coronavirus (Sohrabi et al., 2020). This new 
virus has since spread to most parts of the world, causing massive number of deaths which 
has led to an ongoing pandemic. In January 2020, the World Health Organisation (WHO) 
recommended that the interim name of the disease caused by this coronavirus should be 
“2019-nCoV acute respiratory disease” (where „n‟ is for a novel, and „CoV‟ is for 
coronavirus). 
 
The new strain of the coronavirus was eventually named as SARS-CoV-2 by the International 
Committee on Taxonomy of Viruses (ICTV) on the 11
th
 February 2020. On the same day, 
following previously developed guidelines with the World Organisation for Animal Health 
(OIE) and the Food and Agriculture Organisation of the United Nations (FAO), the WHO 
announced and confirmed the new name for the disease caused by SARS-CoV-2 as “COVID-
19” (WHO, 2020). The WHO concluded that the SARS-CoV-2 is transmissible from humans 
to humans through the inhalation of respiratory droplets from coughs and sneezes (6 feet) as 
well as via indirect contact through contaminated surfaces (Morawska & Cao, 2020). 
Common symptoms include fever, cough, shortness of breath, loss of smell and taste, while 
complications could result in pneumonia, acute respiratory distress syndrome, kidney failure, 
viral sepsis and cytokine release syndrome (Paules et al., 2020).
 
 
The emergence of this novel human coronavirus has become a global health concern which 
has led to a worldwide pandemic, disrupting global health security and economy. As of 14
th
 
June 2020, there were more than 7.5 million cases and approximately half a million death 
worldwide (WHO, 2020). Till now, there is neither a vaccine to stop the transmission of the 
SARS-CoV-2 virus nor effective antiviral drugs to cure and combat the COVID-19 disease 
(Paules et al., 2020). Given that there is no cure for COVID-19, it is imperative to explore 
other options to contain the propagation of the infection, especially about its transmission. 
The oral cavity is a significant point of entry for pathogenic agents, which is linked to the 
elocutionary process of SARS-CoV-2 especially in the inhalation of ambient particles in the 
air and the expectorations, considering that SARS-CoV-2 is abundantly present in 
nasopharyngeal and salivary sections of affected patients (Morawska & Cao, 2020; WHO, 
2020). 
 
Mouthwashes contain a wide variety of active ingredients which have been proven to modify 
the oral microbiota as well as reduce the viral load presence in the mouth. In particular, the 
efficacy of mouthwashes in inhibiting viruses such as Herpes Simplex Virus (HSV), Human 
Immunodeficiency Virus (HIV), Middle East Respiratory Syndrome Coronavirus (MERS-
CoV) and Modified Vaccinia Virus Ankara (MVA) have been reported (Baqui, 2001 & 
Eggers, et al., 2015). The objective of this paper is to review the available evidence 
surrounding the efficacy of mouthwash in reducing viral load of viral infections which could 
be beneficial in the case of COVID-19. 
 
Materials and Method 
We searched academic, English-scripted papers published between December 2019 and May 
2020 on PubMed, MEDLINE, ScienceDirect, EMBASE, www.clinicaltrials.gov, WHO and 
the Cochrane Library databases. We searched for journals published between December 2019 
and May 2020 and reviewed the reference lists of the included studies. 
 
Search Strategy and Selection Criteria 
The search phrases used included (mouthwash AND viral infection), (mouthwash trials AND 
COVID-19) and (Adults with respiratory viral infections on toothpaste). The keywords used 
were checked with the Medical Subject Headings (MESH) database. We used the Preferred 
Reporting Items for Systematic Review and Meta-analysis (PRISMA) flow chart (See Figure 
1) to shows the flow chart of the articles included. 
 
The titles and abstracts of all these articles were reviewed and a total of 98 studies excluded 
in addition to the removal of duplicate items identified through multiple database sources. 
The remaining articles were screened for quality by excluding the studies in which the subject 
matter was not directly addressed or evaluated. 35 records were excluded thereafter, while the 
remaining 44 articles were assessed for eligibility by a full text review. At the end of the 
review, five studies were entered into the final evaluation process. Details of the search 
strategy are given in the PRISMA diagram. All the results shown were evaluated and the 
articles that directly evaluated the subject matter were included in the final review (N = 5). 
 
Inclusion criteria 
We included all papers that relates to the subject matter as restriction were not placed on 
language and date of publication or articles in the resources found. This was due to the 
paucity of relevant studies relating to the subject matter.  
 
Exclusion criteria 
We excluded adults diagnosed with bacterial infections and people with underlying health 
conditions who had mouthwashes interventions. This is because such individuals are often 
placed on a different anti-microbial treatment plan, which might interfere with the study on 
the anti-viral efficacy of mouthwashes. Children and people with mental health conditions 
were excluded for us to conduct a more focused review. 
 
Data collection and data analysis 
Two review authors independently assessed the eligibility and quality of the retrieved papers 
using the Jadad scale. We were unable to conduct a meta-analysis of study outcomes, given 
the small number of included studies and their heterogeneity nature. Consequently, we did a 
narrative review to report on various types of mouthwashes trialed for reducing viral 
infections in people across multiple populations. We used the Population, 
Intervention/Indicator, Comparison, Outcome (PICO) to analyse the data retrieved. We 
provided a tabular summary of research findings on the efficacy of mouthwashes in reducing 
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PVP-I 7% mouthwash 
was diluted 1:30 with 
water to a concentration 
of 0.23%.  
 
PVP-I 7% gargle/mouthwash 
showed rapid viricidal efficacy in 
vitro at a concentration of 0.23% 
PVP-I. This suggests that the 
ingredient could provide a 
protective oropharyngeal hygienic 
measure during this pandemic.  
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sterile distilled waste 
for control patients 
A significant difference (p < 0.05) 
was found between the control 
group and the experimental group 
at 30 min post rinse. 
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Each virus was missed 
with an equal volume of 
Listerine for 30 seconds 
to 5 minutes, and the 
residual infectivity of 
the virus was assessed.  
Exposure to Listerine for 30 
seconds had an antiviral  
effect against herpes simplex type 1 
and 2 (96.3 and 100% respectively), 
Influenza A (100%). At 5 minutes  
exposure, Listerine resulted  
in a 21.5% and  
33.4% reduction in Rotavirus  
and Adenovirus respectively  
(Yamanaka 
et al. 1994) 
Direct 
Exposure  
Listerine  MRSA & HIV The viruses were 
exposed to Listerine for 
30 seconds and the viral 
load measured 
afterwards  
60% of HIV was inactivated 
by a 30 second exposure to  
50% Listerine, while exposure for 
30 seconds to Listerine  
killed MRSA completely  
Narrative and Analytical Description of Result 
The first reviewed paper, (Satomura et al., 2005) conducted a randomised trial, water 
gargling, povidone-iodine gargling, and usual care (control) on upper respiratory tract 
infection. Participants were followed for 60 days. Subjects in the two gargling groups were 
requested to rinse with water or diluted povidone-iodine at least three times a day. A Cox 
regression (proportional hazard model) revealed the efficacy of water gargling (hazard 
ratio=0.60, 95% CI=0.39-0.95). 
 
The second reviewed paper, (Eggers et al., 2018) conducted an experimental study using 
Povidone-iodine (PVP-I) 7% in Severe Acute Respiratory Syndrome Middle East respiratory 
syndrome Rotavirus strain Influenza virus subtype (H1N1). PVP-I 7% mouthwash was 
diluted 1:30 with water to a concentration of 0.23%. PVP-I 7% gargle/mouthwash showed 
rapid viricidal efficacy in vitro at a level of 0.23% PVP-I. This finding suggests that the 
active ingredient (PVP-I) present in the mouthwash could provide a protective oropharyngeal 
hygienic measure during this pandemic. 
 
The third reviewed paper (Meiller, T. et al. 2005) randomly assigned 40 patients to two 
treatment groups; mouthwash active ingredient (Listerine) and sterile control water. The 
efficacy of these two treatment groups (Listerine and Water) was tested in reducing the 
presence of viral contamination in oral fluids for at least 30 minutes after oral rinse. The 
paper suggested that the risk of viral cross contamination generated from these oral fluids in 
person to person contact is significantly reduced using Listerine.  
 
The fourth and fifth reviewed papers, (Yamanaka et al., 1994; Dennison, et al., 2005) 
assessed the efficacy of Listerine antiviral effect in the mouth. This active mouthwash 
ingredient (Listerine) was tested against a number of viruses such as Herpes simplex type 1 
and 2, Influenza A Rotavirus, Adenovirus, MRSA and HIV. The result concluded that 




It is not surprising that simple water gargling was inadequate to minimise cross-infection of 
COVID-19 as water has no antiviral properties and as such gargling with water will definitely 
not produce such effect. In addition, given the aggressiveness of COVID-19, it is less likely 
that simple water gargling will be adequate to minimise cross-infection of COVID-19. 
However, gargling with mouthwash ingredients such as povidone-iodine seems to be a 
measure that could be effective in reducing COVID-19 viral load. This is due to its 
established and published potent effect on viruses of the upper respiratory tract as 
corroborated by Meister et al., (2020). The authors (Meister et al., 2020) concluded that 
gargling with mouthwash cannot inhibit the production of viruses in the cells, however it 
could reduce viral load in the short term. This can be particularly useful and related to 
COVID-19 infection where the greatest potential for infection comes from the oral cavity and 
throat.  
 
Another reviewed article, (Eggers et al., 2018), concluded that the active ingredient (PVP-I) 
present in the mouthwash could provide a protective oropharyngeal hygienic measure during 
this pandemic. The use of Povidone-iodine (PVP-I) 7% in Severe Acute Respiratory 
Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Rotavirus strain, Influenza 
virus subtype (H1N1) showed rapid viricidal efficacy. The efficacy of (PVP-I) in showing 
rapid viricidal effect when tested against MERS and SARS, is encouraging and promising, 
considering the fact that they are both closely related to SARS-CoV-2.  
Moreover, the three experimental studies (Dennison, D. et al., 1995; Meiller, T. et al., 2015 
and Yamanaka et al., 2020) trialed Listerine mouthwashes in three different viral infections 
with promising outcomes in patients infected with HIV, Adenovirus and Rotavirus. Given 
that the characteristics of these viruses differ from COVID-19 features, we cannot expressly 
indicate that Listerine will be efficacious in minimizing cross-transmission of COVID-19 
until proven by a future study, however its potent effect on viruses is encouraging and worthy 
of further research. 
 
The five papers reviewed showed that mouthwash is effective in reducing the viral load of the 
viruses tested against it. To buttress this point, a recent paper (Carrouel et al., 2020) 
suggested that active ingredients present in mouthwashes could provide valuable adjunctive 
treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including 
potential SARS-CoV-2 carriage.  
 
Recently, (Farzan & Firoozi, 2020) assessed the appropriate mouthwash to eliminate 
coronaviruses for pre-procedural rinsing in dental practice. The paper concluded that PVP-I is 
a promising substance to eliminate coronaviruses such as SARS-CoV, MERS-CoV and few 
other viruses. To this effect, PVP-I mouthwash is an approved mouthwash for pre-procedural 
rinsing in dental practices to eliminate coronaviruses. More randomised controlled trials are 
currently underway explicitly studying the effect of mouthwashes on SARS CoV-2. 
 
CONCLUSION 
In the absence of vaccines or medicines that have unfortunately arrived too late for many 
dead patients, it is vital that we explore simple day-to-day activities that can be optimised in 
combating this present COVID-19 pandemic. While we do not confirm that mouthwashes 
currently on the market could be used as a panacea for SARS CoV-2, nonetheless, our 
findings provide valuable information on mouthwashes that could possibly be beneficial in 
reducing the viral load of this killer micro-organism.  
 
This review buttresses the evidence that certain commercially available mouthwashes can 
inactivate SAR-Cov-2 virus or reduce the viral load in the throat and mouth. However, the 
mouthwashes are not suitable for treating COVID-19 patients and do not serve as a protective 
mechanism against the virus. There is need for further clinical studies to determine the 
efficacy of mouthwashes on SARS-CoV-2. This could be done in-vitro using cell culture 
experiments and in-vivo experiments which compares the viral loads in the oral cavity and 
throat of COVID-19 patients before and after mouthwash use. 
 
References 
Baqui A., Kelley J., Jabra-Rizk M., DePaola L., Falkler W., & Meiller T. (2001). In vitro 
effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 
1. Journal of Clinical Periodontology. 28(7): 610-616. 
Belouzard S., Millet J., Licitra B., & Whittaker, G. (2012). Mechanisms of Coronavirus Cell 
Entry Mediated by the Viral Spike Protein. Viruses, 4(6): 1011-1033. 
Cecílio A., Cândido A., Resende M., Bontempo E., & Martins A. (2000). Detection of mouse 
hepatitis virus in mouse colonies using the nested polymerase chain 
reaction. ArquivoBrasileiro de MedicinaVeterinária e Zootecnia. 52(4): 307-312. 
 
Carrouel F., Conte M., Fisher J., Gonçalves L., Dussart C., Llodra J., & Bourgeois D. (2020). 
COVID-19: A Recommendation to Examine the Effect of Mouth rinses with β-Cyclodextrin 
Combined with Citrox in Preventing Infection and Progression. Journal of Clinical Medicine. 
9(4): 1126. 
 
Dennison D., Meredith G., Shillitoe E., & Caffesse R. (1995). The antiviral spectrum of 
Listerine antiseptic. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology: 79(4): 442-448. 
 
Eggers M., Eickmann M., & Zorn J., (2015). Rapid and Effective Virucidal Activity of 
Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-
CoV) and Modified Vaccinia Virus Ankara (MVA). Infectious Diseases and Therapy. 4(4): 
491-501. 
 
Eggers M., Koburger-Janssen, T., Eickmann M., & Zorn J. (2018). In Vitro Bactericidal and 
Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral 
Tract Pathogens. Infectious Diseases and Therapy. 7(2): 249-259. 
 
Kendall E, Bynoe M, & Tyrrell D., (1962). Virus Isolations from Common Colds Occurring 
in a Residential School. BMJ, 2(5297): 82-86. 
 
Liu Q., & Gerdts V (2019). Transmissible Gastroenteritis Virus of Pigs and Porcine Epidemic 
Diarrhoea Virus in Module in Life Sciences (Elsevier B.V) 
https://www.sciencedirect.com/science/article/pii/B978012809633820928X Accessed 14 
June 2020. 
 
Keep S M., Bickerton E., & Britton P (2015) in Coronaviruses: Methods and Protocols, (New 
York, Springer Verlag), pp 115 -134. 
 
Meister T., Brüggemann Y., Todt, D., Conzelmann, C., Müller, J., & Groß, R. et al. (2020). 
Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome 
Coronavirus 2. The Journal of Infectious Diseases. 
 
Meiller T., Silva A., Ferreira S., Jabra-Rizk M., Kelley J.,& DePaola L., (2005). Efficacy of 
Listerine Antiseptic in reducing viral contamination of saliva. Journal of Clinical 
Periodontology. 32(4): 341-346. 
 
Morawska L., & Cao J., (2020). Airborne transmission of SARS-CoV-2: The world should 
face the reality. Environment International. 139(1): 105730. 
 
PalM., Berhanu G., Desalegn C., & Kandi V (2020). Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12(3): 7423. 
 
Paules C., Marston H., & Fauci A (2020). Coronavirus Infections - More Than Just the 
Common Cold. JAMA. 323(8): 707. 
 
Satomura K., Kitamura T., Kawamura T., Shimbo T, Watanabe M., Kamei M., Takano Y& 
Tamakoshi A (2005). Prevention of Upper Respiratory Tract Infections by Gargling: A 
Randomized Trial. American Journal of Preventive Medicine. 29(4): 302-307. 
 
Schalk A (1931). An apparently new respiratory disease of baby chicks. J Am Vet Med 
Assoc. 78(19): 413 - 422. 
Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, & Agha R, 
(2020). World Health Organization declares global emergency: A review of the 2019 novel 
coronavirus (COVID-19). International Journal of Surgery. 76(1): 71-76. 
 
Tyrrell D, & Bynoe M (1965). Cultivation of a Novel Type of Common-cold Virus in Organ 
Cultures. BMJ. 1(5448): 1467-1470. 
 
WHO (2020). Naming the Coronavirus Disease (COVID-19) And the Virus That Causes It. 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it 
Accessed 14 June 2020. 
 
WHO (2020). Coronavirus. 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed 14 June 2020. 
 
WHO (2020). Coronavirus Disease (COVID-19) Situation Report–143. 
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200611-covid-19-
sitrep-143.pdf?sfvrsn=2adbe568_4 Accessed 2 June 2020. 
 
Wood A, & Payne D, (1998). The action of three antiseptics/disinfectants against enveloped 
and non-enveloped viruses. Journal of Hospital Infection. 38(4): 283-295. 
 
Yamanaka A, Hirai K, Kato T, Naito Y, Okuda K, Toda, S. & Okuda K (1994). Efficacy of 
Listerine antiseptic against MRSA, Candida albicans and HIV. Bulletin of Tokyo Dental 
College. 35(1): 23-6. 
